Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer
Phase 3
Completed
- Conditions
- Chronic Myeloproliferative DisordersInfectionLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic Syndromes
- First Posted Date
- 2004-08-24
- Last Posted Date
- 2013-03-26
- Lead Sponsor
- Aronex Pharmaceuticals
- Registration Number
- NCT00002742
- Locations
- ๐บ๐ธ
Scott and White Clinic, Temple, Texas, United States
๐บ๐ธInfections Limited, P.S., Tacoma, Washington, United States
๐บ๐ธRush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
Aroplatin and Gemcitabine in Patients With Advanced Pancreatic Cancer Resistant to Standard Therapies
Phase 1
- Conditions
- Pancreatic Neoplasms
- First Posted Date
- 2004-04-20
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Aronex Pharmaceuticals
- Target Recruit Count
- 111
- Registration Number
- NCT00081549
Aroplatin and Capecitabine in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies
Phase 1
- Conditions
- Colorectal Neoplasms
- First Posted Date
- 2004-04-20
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Aronex Pharmaceuticals
- Target Recruit Count
- 105
- Registration Number
- NCT00081536
A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies
Phase 1
- Conditions
- Esophageal NeoplasmsHepatocellular CarcinomaColorectal NeoplasmsOvarian NeoplasmsPancreatic NeoplasmsNeoplasms
- First Posted Date
- 2003-04-02
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Aronex Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT00057395
- Locations
- ๐บ๐ธ
John Wayne Cancer Institute, Santa Monica, California, United States
A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies
Phase 2
- Conditions
- Colorectal Neoplasms
- First Posted Date
- 2002-08-08
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Aronex Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT00043199
- Locations
- ๐บ๐ธ
Arizona Cancer Center, Tucson, Arizona, United States
๐บ๐ธUniversity Medical Center, Tucson, Arizona, United States
Safety and Effectiveness of Zintevir (AR177) Given to HIV-Infected Patients
Phase 1
Completed
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Aronex Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT00002403
- Locations
- ๐บ๐ธ
Cornell AIDS Clinical Trials Unit, New York, New York, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath